Clinical Trials on Dual GLP-1/GIP Agonists Tirzepatide: Combining GLP-1 and GIP for Enhanced Weight Loss Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist developed to enhance weight loss beyond that achieved with GLP-1 receptor agonist monotherapy
As a result, negative feedback, receptor desensitization and SRIF secretion are reduced relative to the increased GHRP influence causing in turn, greater recrudescence of somatotroph function with increased hGH and IGF-1 production
Am J Phys 273(5):E981E9E8 Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
WW states that these doctors are obesity specialists and will be able to recommend appropriate treatment plans to suit your health goals
The informal name for combining BPC-157 and TB-500, two peptides studied for tissue repair
,aspect=fit)
